Literature DB >> 29888440

Kawasaki disease shock syndrome: Unique and severe subtype of Kawasaki disease.

Luisa Berenise Gamez-Gonzalez1, Isabel Moribe-Quintero2, Martin Cisneros-Castolo3, Javier Varela-Ortiz4, Mireya Muñoz-Ramírez5, Martin Garrido-García6, Marco Yamazaki-Nakashimada2.   

Abstract

BACKGROUND: Kawasaki disease shock syndrome (KDSS) is an uncommon presentation of Kawasaki disease (KD). KDSS has been associated with more severe markers of inflammation, coronary abnormalities and i.v. immunoglobulin (IVIG) resistance.
METHODS: A retrospective, descriptive study of children with KDSS in two hospitals was performed. Relevant articles about KD and shock were collected, and demographic data, clinical presentation, laboratory variables, echocardiogram findings, treatment and special features were analyzed when available. Twelve patients diagnosed with KDSS were retrospectively reviewed from two centers in Mexico, along with 91 additional cases from the literature.
RESULTS: Seventy-two patients presented with complete KD (69.9%), and 30.1% (31/103) had unusual KD manifestations. The most frequent diagnosis at the time of admission was toxic shock syndrome (TSS; n = 20). Sixteen of the 20 had coronary artery abnormalities. Overall, abnormalities in the coronary arteries were documented in 65% of the patients. The mortality rate was 6.8%.
CONCLUSION: The presence of coronary aneurysms was significantly and positively correlated with male gender, IVIG resistance, inotrope treatment, cardiac failure, abdominal pain and neurological symptoms. IVIG-resistant patients had higher neutrophil : lymphocyte ratio. Abdominal symptoms, hypoalbuminemia and elevated C-reactive protein were present in almost all of the patients. Multisystem involvement with atypical presentation in KDSS is frequent. An important differential diagnosis is TSS. Mechanical ventilation, gastrointestinal and neurological symptoms were associated with IVIG resistance and the presence of coronary aneurysms. The first line of treatment includes IVIG and pulse corticosteroids; in severe cases, infliximab, anakinra, cyclosporine or plasmapheresis are alternative treatment options.
© 2018 Japan Pediatric Society.

Entities:  

Keywords:  Kawasaki disease; Kawasaki disease shock syndrome; atypical Kawasaki disease; shock; toxic shock syndrome

Mesh:

Substances:

Year:  2018        PMID: 29888440     DOI: 10.1111/ped.13614

Source DB:  PubMed          Journal:  Pediatr Int        ISSN: 1328-8067            Impact factor:   1.524


  29 in total

1.  A 13-Year-Old Boy Who Has Kawasaki Disease Shock Syndrome Presents with Parotitis.

Authors:  Yilmaz Yozgat; Selcuk Uzuner; Aysegul Dogan Demir; Mustafa Ogur; Can Yilmaz Yozgat; Ozden Turel
Journal:  J Pediatr Intensive Care       Date:  2019-10-09

Review 2.  Kawasaki shock syndrome in an Arab female: case report of a rare manifestation and review of literature.

Authors:  Ahmed A Nugud; Assmaa Nugud; Deena Wafadari; Walid Abuhammour
Journal:  BMC Pediatr       Date:  2019-08-23       Impact factor: 2.125

3.  Pediatric expert consensus on the application of glucocorticoids in Kawasaki disease.

Authors: 
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2022-03-15

4.  Is multisystem inflammatory syndrome in children on the Kawasaki syndrome spectrum?

Authors:  Rae Sm Yeung; Polly J Ferguson
Journal:  J Clin Invest       Date:  2020-11-02       Impact factor: 14.808

Review 5.  Perspective of Immunopathogenesis and Immunotherapies for Kawasaki Disease.

Authors:  Lung Chang; Horng-Woei Yang; Tang-Yu Lin; Kuender D Yang
Journal:  Front Pediatr       Date:  2021-07-19       Impact factor: 3.418

6.  Neurological involvement associated with COVID-19 infection in children.

Authors:  Tai-Heng Chen
Journal:  J Neurol Sci       Date:  2020-08-13       Impact factor: 3.181

7.  Observation on the clinical effect of high-dose Intravenous Immunoglobulin combined with low-dose prednisone acetate in the treatment of patients with Kawasaki Disease.

Authors:  Hao Zhang; Mei-Ying Wang; Yong-Nan Teng; Xiao-Dan Wang; Hai-Tao Cao
Journal:  Pak J Med Sci       Date:  2021 Jul-Aug       Impact factor: 1.088

Review 8.  Similarities and Differences Between COVID-19-Related Multisystem Inflammatory Syndrome in Children and Kawasaki Disease.

Authors:  Min-Sheng Lee; Yi-Ching Liu; Ching-Chung Tsai; Jong-Hau Hsu; Jiunn-Ren Wu
Journal:  Front Pediatr       Date:  2021-06-18       Impact factor: 3.418

9.  Kawasaki disease epidemic: pitfalls.

Authors:  Romina Gallizzi; Giovanni Corsello; Giovanni Battista Pajno
Journal:  Ital J Pediatr       Date:  2020-08-27       Impact factor: 2.638

Review 10.  Anakinra Therapy for Non-cancer Inflammatory Diseases.

Authors:  Giulio Cavalli; Charles A Dinarello
Journal:  Front Pharmacol       Date:  2018-11-06       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.